Sheila Gujrathi, M.D.
Dr. Gujrathi is the cofounder and former Chief Executive Officer of Gossamer Bio, Inc., which is discovering and developing a clinical and research pipeline of novel therapeutics for immunology, inflammation, and oncology. She serves as the Chair of the Board of Directors of ADARx Pharmaceuticals, Inc.. She previously served as Chair of the Board of Directors of Turning Point Therapeutics, Inc. and on the Board of Directors at Five Prime Therapeutics, Inc. (acquired by Amgen Inc.) and Ambrx, Inc. (acquired by a consortium of investors). Dr. Gujrathi is an Ernst & Young Entrepreneur of the Year awardee. Prior to Gossamer Bio, Dr. Gujrathi served as Chief Medical Officer of Receptos, Inc. (acquired by Celgene Corp.). At Receptos, she built the development, regulatory and quality organizations and advanced the pipeline of drug candidates, including Zeposia®, which is approved for multiple sclerosis and for ulcerative colitis. Prior to Receptos, Dr. Gujrathi was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS), where she led late-stage clinical development and supported numerous global regulatory filings and approvals for Orencia® and Nulojix®. She was also responsible for development of other assets in the BMS immunology clinical pipeline and advised the strategies for discovery, early development, and external business development within the immunoscience franchise. Prior to BMS, Dr. Gujrathi held roles in the immunology, tissue growth and repair clinical development groups at Genentech, Inc. where she worked on Ocrevus®, Rituxan®, Xolair®, and a number of other programs across all stages of development and served as the Avastin® franchise team leader. Earlier in her career, she was a management consultant in McKinsey & Company’s healthcare practice.
Dr. Gujrathi received both her M.D. in the accelerated Honors Program in Medical Education and her B.S. in biomedical engineering with highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital and Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford.